Richmond Pharmacology Confirm event with the Department of International Trade

Posted:

August 2018

Richmond Pharmacology is delighted to confirm an upcoming event alongside the Department of International Trade in the US.Early Phase Drug Development in the UK is to take place Friday 28th of September in Boston, MA.

Click here to RSVP

The event which is to host speakers from both Richmond Pharmacology and UK regulators continues a long line of events staged between Richmond Pharmacology and the DIT around the world. Full details found below including how to express interest in attending the event.

Friday, 28 September 2018Time TBC

Café ArtScience650 East Kendall St,Cambridge, MA 02142

Click here to RSVP

Full schedule to follow, please email j.wilmott@richmondphramacology.com confirm interest in attending.

Supported By:

Back to news

More about us Adaptive Phase I & IIa Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.